Overview

A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers

Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
0
Participant gender:
All
Summary
20 healthy participants will be evaluated for tolerability and safety of a new eye drop formulation for treatment of Dry Eye Syndromes, Oph1 0.5% Cyclosporine A (CsA) compared with Restasis 0.05% CsA ophthalmic formulation.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
OphRx Ltd.
Treatments:
Cyclosporine
Cyclosporins
Criteria
Inclusion Criteria:

1. Male or female aged 20-50 years, inclusive.

2. Systemically and ophthalmologically healthy subjects evaluated during the clinical
history.

3. Best-corrected visual acuity (BCVA) 20/40 or better in both eyes.

4. Negative Fluorescein staining in Fluorescein Corneal staining (FCS) in both eyes.

5. Up to 0.5 Conjunctival redness in Conjunctival redness without slit lamp, in
standardized lighting conditions, in both eyes.

6. IOP (< 22mmHg), in both eyes.

7. No pathology findings in Slit-lamp biomicroscopy in both eyes.

8. Ability to comply with the requirements of the study and complete the questionnaire
and a full sequence of protocol-related evaluations.

9. Ability to understand and provide written informed consent.

10. In the judgement of the investigator, the participant can safely perform study
activity.

Exclusion Criteria:

1. Have chronic systemic disease of any form known.

2. In the case of women: be pregnant, breastfeeding or planning to become pregnant within
the study period or women without a history of hysterectomy, oophorectomy, who do not
ensure a hormonal contraceptive method or intrauterine device during the study period.

3. Be a user of topical ophthalmic products of any kind.

4. Being a chronic drug user.

5. Be a user of contact lenses.

6. Have a history of any type of eye surgery.

7. Participating in clinical research studies 90 days prior to inclusion in the present
study.

8. In the judgement of the investigator, any condition that could interfere with the
intent of the study or would make participation not in the best interest of the
participant.